With ground breaking cystic fibrosis treatment data, Vertex (Nasdaq: VRTX) shares surged 40% in a single day last week. Kalydeco is already approved to treat are rare mutation occurring in 5% of cystic fibrosis suffers, but by combining it with experimental drug VX-809, Vertex is potentially bringing its treatment to nearly half of the CF population. Vertex's drugs special is that they treat the underlying cause of the disease and not just attempt to mitigate symptoms.

In this episode of Where The Money Is, Motley Fool health care analysts David Williamson and Michael Douglass give investors the background of Vertex, explain the sales potential of the CF treatment, discuss some concerns with the data, and whether it is to late to jump on the stock's bandwagon.